Articles On Exopharm (ASX:EX1)

Melbourne biotech company Exopharm (ASX:EX1) has received firm commitments from institutional and sophisticated investors to raise $12 million, double the minimum raise amount. The 16.7 million new shares will be priced at 72c, three times...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Summary Exopharm obtained firm commitments from institutional and sophisticated investors to raise a total of AU$12 million. Race Oncology announced that its new Chief Medical Officer, Dr David Fuller, is set to join on 1 July 2021....

Exopharm (ASX:EX1) says it has received 'firm commitments' from institutional and sophisticated investors for 16,666,667 shares to raise a total of $12 million in a placement.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With stock...

Source: smolaw, Shutterstock Summary A leader in human clinical therapeutics, Exopharm Limited today provided its quarterly update highlighting the growing interest in exosome medicines. The Company is investing in two interrelated te...

Source: katjen, Shutterstock The market could not extend yesterday's gains to today's session and traded in the red by lunchtime. It dropped 19.30 points and traded at 7039.30, down by 0.30%. Energy remained the worst performing sector. 6...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Pitt Street Research has initiated coverage on Melbourne biotech company Exopharm (ASX:EX1), declaring it is currently significantly undervalued and could be re-rated by the market. In a 29-page research report, Pitt Street Research lauded...

Source: Ratanapon Srisuneton, Shutterstock Summary Universal Biosensors has entered into exclusive agreements for the commercialisation and development of its biosensors. Avecho has received ethics approval to conduct an Australian Ph...

Source: Oleksiy Mark, Shutterstock Summary Exopharm reported positive safety outcomes and validation of the manufacturing process in its PLEXOVAL II phase 1 trial. The Company said that these trial outcomes validate its LEAP manufactu...

The Exopharm Ltd (ASX: EX1) share price rocketed today after the company announced positive clinical trial results for its regenerative medical product, Plexaris. At market close, the Exopharm share price is up by 12.93% today to 65 cents...

Shares in Exopharm (ASX:EX1) jumped this morning after the Melbourne biotech announced it was building multiple revenue streams and positive data confirming the safety of its off-the-shelf exosome product, Plexaris. Exopharm said it had sig...

Exopharm (ASX:EX1), which is developing medicines using exosomes from cells, has announced data from a preclinical study of its Cevaris product.

Wall Street finishes on record highs again after strong US jobs data Dow Jones and S&P500 closed on Monday at record highs once again, following the US jobs data on Friday that showed almost 1 million jobs were added in March, and unemp...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

The Exopharm Ltd (ASX: EX1) share price is tumbling today after the company released its preclinical data from its osteoarthritis animal study, showing its two regenerative medical products had no effect on the rats studied. At the time of...

Special Report: Exopharm (ASX:EX1) is picking up steam as the scientific community wakes up to the huge therapeutic potential of ... Read More The post Exopharm preps for great LEAP forward as world catches onto exosome promise appeared fir...

Special Report: Melbourne biotech Exopharm (ASX:EX1) has solved a crucial bottleneck in the production of exosomes, creating an easily scalable ... Read More The post Exopharm’s LEAP technology a breakthrough in exosome therapeutics appeare...

Special Report: Biotech company Exopharm has begun its second human clinical trial using extracellular vesicles isolated from human platelets, solidifying ... Read More The post Exopharm has just dosed it first patient in a wound-healing st...

ShareCafeHidden Gems Webinar Recap – NMT, EX1, DCC, OVN Catch up on the full webinar with presentations from Neometals, Exopharm, DigitalX and Oventus Medical. Hidden Gems Webinar Recap – NMT, EX1, DCC, OVNCompany News

ShareCafeExopharm – Hidden Gems Webinar Presentation   Presenter – Chris Baldwin – Chief Operating Officer – Exopharm is an Australian regenerative medicine biopharmaceutical company that will develop and commercialise extracellular vesicl...

A quick wrap of the ASX’s key winners and losers on Thursday, August 27. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 760 stocks rose, 634 declined and...

Canary Capital is making a huge bet on a company that thinks stem cells aren’t the future of medicine. The small- and micro-cap Sydney investment house has just finished a $10m capital raising for regenerative medicine company Exopharm, a M...

ShareCafeExopharm’s Big Idea Heading For A Big Business In EV Medicines Everyone is familiar with how quickly a big idea can become a big business – just think of Uber, or Afterpay, or even A2 Milk. Most of us use and consume these goods an...

Clinical stage regenerative medicine company Exopharm (ASX: EX1) has published test results that suggest its Plexaris product, made up of engineered exosomes through “Leap technology”, can effectively deliver therapeutic drugs into target c...

Smartphone screen protector maker Nanoveu (ASX:NVU) is running hard this morning after receiving more proof that its antiviral screen cover can kill coronavirus — just not the one everyone is talking about. Montana lab Bioscience Laboratori...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

The COVID-19 pandemic has led to 527 clinical trials being shut down in Australia and New Zealand the last two months, up 36 per cent on the prior two months as many organisations deem the patient risk of exposure to be too high. Globally,...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Regenerative medicine company Exopharm (ASX: EX1) has received amiable results from a BioMAP testing program operated by Eurofins with respect to its exosome products. Results showed that Exopharm’s exosome platform is safe in its mechanism...

Many regenerative medicine companies on the ASX specialise in stem-cell therapies but Exopharm (ASX:EX1) is pursuing exosomes instead. Exosomes, also known as Extra-corporeal Vesicles, are microscopic cellular couriers. These shift proteins...

Melbourne-based regenerative medicine company Exopharm (ASX:EX1) has announced the first dosing has occurred in the PLEXOVAL phase 1 study using exosomes isolated from human platelets for wound healing.

Cann Group (ASX:CAN) is pulling back from its original ambitious Mildura cannabis growing warehouse, saying a global oversupply has led it to change plans. Furthermore, major shareholder Aurora says it won’t participate in any new funding r...

Exopharm (EX1) has announced the first dosing has occurred in the PLEXOVAL Phase 1 study using exosomes PLEXOVAL is a world-first study using a platelet-derived exosome product made from the company’s wound healing LEAP technology Exosomes...

The science of Regenerative Medicine is a rapidly emerging field linking the medical technology, biotechnology and pharmaceutical sectors, and holds much potential to deliver better patient outcomes and drive economic growth.  Regenerative...

Regenerative medicine company Exopharm (ASX:EX1) has announced the start of its PLEXOVAL Phase 1 study, the first human clinical trial using exosomes for wound healing.

Want to know when shares are coming out of escrow? We’ve been keeping tabs, so you don’t have to. Every two weeks, Stockhead takes a look at the small cap companies that are releasing shares that have been locked away in escrow. Escrow refe...

Special Report: Stem cells still have somewhat of a bad rep, as news headlines either repeat the embryo origin story or recount shills promising them as a cure-all for everything from ADHD to Alzheimer’s. But beneath those headlines is a fl...